Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Rhea-AI Summary

Keros Therapeutics (NASDAQ:KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences.

CEO Jasbir S. Seehra will present at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET in a fireside chat format, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 12:00 p.m. ET as a corporate presentation. Replays will be available on the company's investor relations website for 90 days after each event.

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

2025 Wells Fargo Healthcare Conference

• Date and Time: Thursday, September 4, 2025 at 2:15 p.m. Eastern time
• Link: https://cc.webcasts.com/well001/090325a_js/?entity=140_M0POL3S
• Format: Fireside Chat Presentation
  

H.C. Wainwright 27th Annual Global Investment Conference

• Date and Time: Tuesday, September 9, 2025 at 12:00 p.m. Eastern time
• Link: https://journey.ct.events/view/fc069aa9-dccd-4e96-b187-8f4298ea39db
• Format: Corporate Presentation
  

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Contacts

Investor Contact:
Justin Frantz
jfrantz@kerostx.com 
617-221-6042

Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

FAQ

When is Keros Therapeutics (KROS) presenting at the Wells Fargo Healthcare Conference 2025?

Keros Therapeutics will present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. Eastern time in a fireside chat format.

When is KROS presenting at the H.C. Wainwright Conference 2025?

Keros will present at the H.C. Wainwright Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time as a corporate presentation.

Where can I watch the replay of Keros Therapeutics' conference presentations?

Replays will be available in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days after each event.

What is Keros Therapeutics' main focus as a company?

Keros is a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins.